Support in USA : 1-978- 707-9553 / Support in India : +91- 9987711567

  • Apple Pharmaceuticals

Lopimune

HIV-AIDS-Cipla-Lopinavir-200mg-Ritonavir-50mg-Lopimune

Availability: In stock

Special Price $ 110

BRAND : Lopimune
STRENGTH : 200mg & 50mg
INGREDIENT : HIV-AIDS-Cipla-Lopinavir-200mg-Ritonavir-50mg-Lopimune
COMPANY NAME : Cipla
COUNT : 60 Tablets



Description of Lopimune

Trade name: Lopimune Active ingredients: Lopinavir and Ritonavir Strength of the ingredients: Lopinavir 200mg and Ritonavir 50mg Mfg: cipla Container: 60 tablets Classified: as anti-retroviral drug Lopimune description: Lopimune tablet is a cipla product, which exhibits anti-retroviral property. Lopimune tablet is a combination of Lopinavir 200mg and Ritonavir 50mg Both prime active ingredients containing anti-viral activity against human immunodeficiency virus (HIV) which is responsible for causing AIDS Lopimune is inhibiting the progression of HIV virus from multiplication. Lopimune tablet is used to reduce problem related to AIDS, it is not cure or prevent the disease. Lopimune combination helps to postpone the symptoms caused by HIV/AIDS.

Pharmacology of Lopimune

Mechanism of action: Lopimune is an anti viral medicine that has two prime compounds which are inhibitors of HIV protease and effective against retrovirus. Retrovirus has capable of converting RNA into DNA with the help of reverse transcriptase enzyme. Then the viral DNA incorporated into DNA of affected immune cells and then multiplied Anti viral activity of Lopimune is exhibited by Lopinavir; it is a virulent protease inhibitor which inhibits the separation of Gag-Pol polyprotein. Gag-Pol polyprotein is most important protein in the augmentation of active virus. This viral proteases enzyme breaks the Gag-Pol polyprotein at the last stage of multiplication, an active and grown virus released into infected immune cells. A Lopimune tablet prohibits the proteases enzyme that leads to formation of premature, non-infectious viral particles. Pharmacokinetics: Absorption: After oral administration, ritonavir present in Lopimune tablet inhibits the metabolism of Lopinavir; therefore the plasma level of Lopinavir is elevated. The peak plasma concentration of the Lopinavir occurs only at 4 hours after administration The effect of food, there is no significant difference between fasted and fed condition. Lopimune should be taken with or without food. Distribution: The drug Lopinavir is highly bound to the human plasma protein around 98-99%. Metabolism: Lopinavir is undergoes oxidative metabolism, it is metabolized by CYP3A isoenzymes. Ritonavir is a potent CYP3A inhibitor, prohibits metabolism of Lopinavir and increased the plasma level of Lopinavir. Elimination: Lopimune is highly excreted through urine and feces. Lopinavir is a potent protease inhibitor which is responsible for anti viral activity. The terminal half life period is approximately 2.33 hours in case of twice daily, 2.44 hours at once daily.

Indication of Lopimune

Lopimune is primarily indicated for; HIV infection associated AIDS Generally, Lopimune is used as combination with other anti-retroviral medicines. Lopimune is used to suppress the progression of HIV virus in immune cells, and increase T cell counts. The number of Lopinavir blockade associated substitutions affects the virologic action of Lopimune

Dose & Dosage's of Lopimune

Lopimune tablet should be taken with or without food. Lopimune is available in fixed dose combination (Lopinavir 200mg + ritonavir 50mg) In adults: Lopimune 400mg/100mg should be given as 200mg/50mg as two tablets two times a day Lopimune 800mg/200mg should be taken as 200mg/50mg as four tablets once a day. Lopimune should not administered as a single dose, in case of combination with carbamazepine, Phenobarbital, or phenytoin Combinational therapy: Lopimune should be combined with some other anti-viral medicines; Efavirenz Nevirapine Nelfinavir By combining with the above mentioned anti-viral medicines, the prescribed dose of Lopimune is 500mg/125mg, it is taken as 200mg/50mg as two tablets & 100mg/25mg as one tablet at two times a day in concomitant with efavirenz, nevirapine, Nelfinavir In pediatric: The dose of Lopimune in children is recommended on the basis of; Body weight or Body surface area (BSA) Lopimune is not given as single dose for pediatric patients who are under the age of <18 years Lopimune not combined with efavirenz, nevirapine, Nelfinavir 15kg to 25kg: The BSA should be ≥0.6 to <0.9, the prescribed dose of Lopimune 100mg/25mg as two tablets two times a day >25kg to 35kg: BSA- ≥0.9 to <1.4, the recommended dose of Lopimune 100mg/25mg as three tablets two times a day >35kg: BSA ≥1.4, the dose should be taken as Lopimune 100mg/25mg tablets as four tablets or two Lopimune 200mg/50mg tablets. Lopimune combined with efavirenz, nevirapine, Nelfinavir 15kg to 20kg: The BSA should be ≥0.6 to <0.8, the prescribed dose of Lopimune 100mg/25mg as two tablets two times a day >20kg to 30kg: BSA- ≥0.8 to <1.2, the recommended dose of Lopimune 100mg/25mg as three tablets two times a day >30kg to 45kg: BSA ≥1.2 to <1.7, the dose should be taken as Lopimune 100mg/25mg tablets as four tablets or two Lopimune 200mg/50mg tablets. >45kg: BSA ≥1.7, Lopimune 100mg/25mg taken as 5 tablets at twice daily

Side Effects of Lopimune

Blood and lymphatic system: Anemia, leucopenia, neutropenia, lymphadenopathy Cardiac problems: Atherosclerosis such as myocardial infarction, atrioventricular block Ear and labyrinth problems: Vertigo, tinnitus Endocrine: Hypogonadism Eye: Visual impairment GIT: Diarrhea, nausea, vomiting, abdominal pain, gastroenteritis, colitis, dyspepsia, pancreatitis, ulcers, dry mouth General: Fatigue, asthenia Hepatic disorders: AST, ALT and GGT elevation, hepatomegaly, cholangitis, hepatic steatosis Immuno disorders: Hypersensitivity reaction like; urticaria and angioedema Infections and infestation: Upper and lower respiratory tract infection, cellulitis, folliculitis and furuncle Metabolism: Hypercholesterolemia, hyper triglycerides, weight decreased, loss of appetite Musculoskeletal: Arthralgia, back pain, Myalgia, rhabdomyolysis Nerve disorders: Headache, insomnia, neuropathy, ageusia, convulsions Renal: Renal failure, Hematuria, nephritis Reproduction: Erectile dysfunction, amenorrhea, menorrhagia Skin: Rashes, seborrheic dermatitis, night sweats, Pruritus, alopecia, capillaritis, vasculitis

Contraindication of Lopimune

Lopimune is contraindicated to any active ingredients that present in Lopimune tablet; Produce anaphylactic reactions like toxic epidermal necrolysis, Stevens-Johnson syndrome, Erythema multiforme, urticaria, angioedema etc Lopimune is concomitant with potent CYP3A inducers; it leads to contraindicated causes depletion of plasma concentration of Lopinavir that leads to loss of virologic response Some of medicines contraindicated to Lopimune; Alfuzosin with Lopimune: increase concentration of Alfuzosin causes hypotension Rifampin with Lopimune: loss of virologic response and resistance to Lopimune happens Cisapride or pimozide with Lopimune: causes cardiac arrhythmia St. Johns wort causes resistance of Lopimune Lovastatins, simvastatin causes myopathy along with rhabdomyolysis Midazolam with Lopimune: increased sedation, respiratory depression

Drug Interaction of Lopimune

Some of the medicines involved in drug interaction while taking with Lopimune; HIV-1 proteases inhibitors like Fosamprenavir/ritonavir, Indinavir, Nelfinavir (should not administered as a single dose with Lopimune), ritonavir, saquinavir, tipranavir Non-nucleoside reverse transcriptase inhibitors: efavirenz, nevirapine, delaveridine Nucleoside reverse transcriptase inhibitor: tenofovir, abacavir, zidovudine Amiodarone, lidocaine, quinidine, vincristine, vinblastine, dasatinib, nilotinib, rivaroxaban, etc

Precaution of Lopimune

Caution should be taken; Pregnancy women Breastfeeding Hepatic impairment Geriatric patients

Usage & Safety profile of Lopimune Pregnancy & Lactation

Pregnancy category: C Lopimune is not recommended for pregnancy women or who become pregnant. Lopimune cause harm to unborn babies To avoid risk of infection, Lopimune is not given to breastfeeding mothers.

Storage of Lopimune

The Storage condition of Lopimune should between 20oC – 25oC (68oF-77oF). Lopimune should be keep away from moisture, heat, and light